[{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"LB Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"LB Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"N-methyl amisulpride","moa":"Dopamine","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"N-Methyl Amisulpride","moa":"5-HT receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"LB Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LB Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"N-Methyl Amisulpride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Series C Financing","leadProduct":"N-Methyl Amisulpride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by LB Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : The net proceeds from the proposed financed will focus on the development of LB-102, which is an N-methylated analogue of amisulpride under development to treat schizophrenia.

Brand Name : LB-102

Molecule Type : Small molecule

Upfront Cash : Undisclosed

January 24, 2024

Lead Product(s) : N-Methyl Amisulpride

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Phase II

Sponsor : Undisclosed

Deal Size : $75.0 million

Deal Type : Series C Financing

blank

02

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : LB-102, a more lipophilic version of amisulpride, was designed to improve on amisulpride’s notoriously poor membrane (BBB) permeability while matching amisulpride’s binding affinity to the D2/D3 and 5HT7 receptors (critical to the treatment of schizo...

Brand Name : LB-102

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 19, 2022

Lead Product(s) : N-Methyl Amisulpride

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : LB-102, or N-methyl amisulpride, is a patented derivative of amisulpride, a dopamine/5-HT7 antagonist successfully used to treat schizophrenia in Europe for decades.

Brand Name : LB-102

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 04, 2021

Lead Product(s) : N-Methyl Amisulpride

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Proceeds to enable the Company’s continued clinical development of LB-102 for the treatment of schizophrenia.

Brand Name : LB-102

Molecule Type : Small molecule

Upfront Cash : Undisclosed

September 25, 2020

Lead Product(s) : N-Methyl Amisulpride

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Phase II

Sponsor : Undisclosed

Deal Size : $10.0 million

Deal Type : Financing

blank

05

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : LB-102 was well-tolerated up to 150 mg/day. Plasma concentrations of LB-102 were ~2.5 times greater than published values of amisulpride at the same dose, suggesting LB-102 could be dosed substantially lower than amisulpride.

Brand Name : LB-102

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 14, 2020

Lead Product(s) : Amisulpride

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : The ongoing study aims to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of LB-102 in healthy volunteers.

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 22, 2020

Lead Product(s) : Amisulpride

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank